Seventy percent of U.S. women older than 40 years regularly receive clinical breast examination (CBE) as a screening test for breast cancer ( 1 ) , representing 22 million CBEs performed per annum ( 2 ) . Proponents of CBE screening emphasize that in some clinical trials of breast cancer screening, many breast cancers were missed by mammography but detected by CBE ( 3 ) . Others have suggested that the effectiveness of CBE screening can be inferred from one clinical trial in which mammography reduced breast cancer mortality no more than did a carefully conducted, standardized 5-to 10-minute CBE ( 4 ) .
The results of clinical trials, however, may refl ect care delivered under ideal circumstances. Although the sensitivity of screening CBE in clinical trials was approximately 54% ( 5 ) , three studies of community-based screening programs have reported much lower sensitivity, ranging from 28% to 36% ( 6 -8 ) . These studies are limited by the inclusion of women with breast symptoms (who therefore received " diagnostic " examinations) ( 6 ) or have been based on patient samples from novel screening mammography programs that may not refl ect primary care practice ( 7 , 8 ) . Studies of predictors of CBE sensitivity have either examined a limited range of patient-level factors ( 9 ) or have been based on exams performed by nurses ( 7 ) . Failure to diagnose breast cancer with CBE is a leading cause of malpractice claims against primary-care clinicians ( 10 ) , so greater insight is needed regarding current levels of screening CBE accuracy among primary-care clinicians.
We evaluated the cancer detection rate of CBE among asymptomatic women who ultimately died of breast cancer and determined patient characteristics associated with CBE accuracy. Because longer exam duration has been associated with improved lump detection in studies of silicone breast models ( 11 ) , we hypothesized that screening CBE would be less sensitive when performed alongside time-consuming clinical tasks that may shorten CBE duration, such as Pap smear screening or chronic illness care.
M ETHODS

Setting and Subjects
This study was conducted within the Cancer Research Network (CRN), a National Cancer Institute -supported consortium of nonprofi t health maintenance organizations. The CRN consists of the research programs, enrollee populations, and databases of 11 integrated health care organizations that are members of the HMO Research Network. The health care delivery systems participating in the CRN are as follows: Group Health Cooperative, Harvard Pilgrim Health Care, Henry Ford Health System/ Health Alliance Plan, HealthPartners Research Foundation, the Meyers Primary Care Institute of the Fallon Healthcare System/ University of Massachusetts, and Kaiser Permanente in six regions (Colorado, Georgia, Hawaii, Northwest [Oregon and Washington], Northern California, and Southern California). The 11 health plans have nearly 10 million enrollees. The CRN conducts collaborative research on variations in cancer prevention and treatment policies and practices. The subjects were female enrollees from six large health plans in fi ve U.S. states (WA, OR, CA, MN, and MA) whose medical records were reviewed for a case -control study assessing the effectiveness of breast cancer screening. Cases were diagnosed with breast cancer between ages 40 and 65 years in 1983 -1993 and subsequently died of breast cancer. Breast cancer cases were identifi ed from local tumor registries or the regional Surveillance, Epidemiology, and End Results registry, and cause of death was ascertained with standardized review of registry data and medical charts. We included in this study all cases who received screening CBE within 1 year of the date of breast cancer diagnosis (N = 485). We defi ned screening CBE as any CBE performed on an asymptomatic subject that was not performed to evaluate another positive test (e.g., mammography). The study methods were approved by the institutional review boards of the six participating health plans.
Data Abstraction and Defi nitions
The methods of chart abstraction and data quality monitoring have been described previously ( 12 ) . In brief, trained assistants abstracted the following data from medical records: exposure to CBE during the 3-year period prior to initial suspicion of breast cancer; family history of breast cancer; history of breast biopsy; history of natural or surgical menopause; use of estrogen therapy; the Charlson Comorbidity Index ( 13 ) modifi ed to include an additional point for hypertension; and receipt of a Pap smear on the date of CBE. We defi ned a positive family history of breast cancer as chart documentation of breast cancer in any relative.
CBE results were coded as follows: 1) normal, 2) abnormal benign (e.g., fi brocystic changes), 3) indeterminate (e.g., abnormality noted requiring follow-up evaluation), or 4) suspicious of cancer. We defi ned a screening CBE result as positive if it was coded as either indeterminate or suspicious of cancer and negative if it was coded as normal or abnormal benign.
Abstractors noted each date estrogen use was mentioned and whether estrogen was started, stopped, or continued on that date. We classifi ed a woman as an estrogen user if her screening CBE occurred: 1) during a period defi ned by two separate chart notes signifying continuing estrogen use, 2) more than 30 days after starting estrogen therapy and continuation or discontinuation of estrogen was subsequently noted, or 3) within 90 days of an isolated note signifying estrogen continuation. Women were otherwise classifi ed as nonusers or uncertain.
Women were considered peri-or postmenopausal if: 1) menopausal status was specifi cally stated in the chart, 2) the woman had undergone surgical oophorectomy, or 3) symptoms of menopause (e.g., vasomotor instability, irregular menses) were recorded in the chart without a specifi c diagnosis of menopause.
For each subject, we determined the dates of breast cancer diagnosis and initial stage ( 14 ) from either the medical record, local tumor registry, or by linkage with the regional Surveillance, Epidemiology, and End Result registry.
Outcome Measures
The primary outcome was the accuracy of each woman's single, most recent screening CBE before the date of cancer diagnosis. Sensitivity was defi ned as the number of women whose screening CBE was positive divided by the total number of women with breast cancer receiving a screening CBE. Positive examinations among women with cancer were defi ned as true-positive.
Data Quality Assessment
Randomly selected charts were reabstracted by a second reviewer who was masked to the subjects' cancer status, and there was excellent interrater reliability on abstraction results related to screening and diagnostic mammography ( κ ranged from 0.76 to 0.91) ( 12 ) . Three clinicians (MBB, SWF, JGE), also masked to cancer status, reviewed records of women for whom coded events might be questionable (e.g., a screening CBE within 9 months of a prior indeterminate/suspicious screening CBE) and resolved ambiguities by consensus. Coding remained unchanged for 93% of those labeled as screening CBEs and 92% of those labeled as diagnostic CBEs.
Statistical Analyses
We performed descriptive analyses to characterize the subjects demographically and clinically. We estimated standard errors and 95% confi dence intervals (CIs) for sensitivity using the exact binomial distribution. Chi-square tests were used to identify demographic and clinical characteristics associated with sensitivity. When expected values in table cells were 5 or less, we tested for association using either Fisher's exact test or an extension of Fisher's exact test for r × c contingency tables ( 15 ) .
We used logistic regression to identify independent simultaneous patient-level predictors of sensitivity. The binary outcome for these analyses was whether women with cancer had a truepositive screening CBE. Regression models of sensitivity included variables predictive of the outcome in bivariate analyses ( P ≤ .20) and indicator variables for three levels of the modifi ed Charlson comorbidity index, age in 5-year categories, breast cancer stage, and health plan. None of 10 women with stage I breast cancer had a true-positive screening CBE, so the reference group for breast cancer stage included women with either stage I or II. We tested for a linear trend in sensitivity associated with increasing comorbidity by substituting the modifi ed Charlson index as a single ordered categorical variable (coded 0, 1, or ≥ 2). Similarly, we tested for linear trend in sensitivity with increasing breast cancer stage by including breast cancer stage as a single ordered categorical variable (coded 0 for stage I or II, 1 for stage III, 2 for stage IV, and 3 for unstaged). Hypothesis tests were two-sided with a level of signifi cance of 0.05.
R ESULTS
Subject Characteristics
The subjects were aged 40 -65 years with a mean age of 51 years; 26% were nonwhite. Nearly one-quarter of subjects (24%) had a family history of breast cancer, and 20% had had a prior breast biopsy. More than one-third (39%) had at least one chronic disease. The number of subjects from each health plan ranged from 20 to 177. Most women with cancer (86%) had either stage II or III at the time of diagnosis, whereas 12% had stage IV. Women survived a mean of 4.7 years (standard deviation = 2.6) from the date of screening CBE.
Sensitivity of Screening Clinical Breast Examination
The mean interval between screening CBE and breast cancer diagnosis among cases was 151 days (median = 140 days). Of the 485 screening CBEs, the examination was interpreted as suspicious for cancer for 20 women (4.1%), indeterminate for 85 women (17.5%), abnormal benign for 56 women (11.6%), and normal for the remaining 324 women (67.0%). Thus, the screening CBE was either " suspicious for cancer " or " indeterminate " for 105 of 485 women, yielding a sensitivity of 21.6% (95% CI = 18.0% to 25.6%).
Predictors of Sensitivity
Sensitivity was statistically signifi cantly lower among women with a fam ily history of breast cancer, who were using estrogen at the time of the examination, and who received a Pap smear on the date of screening CBE ( Table 1 ) . Sensitivity was lower among women with either stage IV or unstaged cancer at diagnosis and with a comorbidity index of 2 or greater, though these associations did not reach statistical signifi cance. Sensitivity of the breast examination did not differ signifi cantly by age, ethnicity, history of breast biopsy, menopausal status, or year of examination.
In a multiple logistic regression analysis adjusting for age, health plan, cancer stage, family history of breast cancer, and chronic disease comorbidity, the odds of a true positive screening CBE were reduced among women using estrogen (OR = 0.23; 95% CI = 0.07 to 0.80) or who received a Pap smear concurrently with CBE (OR = 0.45; 95% CI = 0.27 to 0.72) ( Table 2 ). In the same analysis, there were non -statistically signifi cant trends toward decreased sensitivity among women with a family history of breast cancer ( P = .051), increasing chronic disease comorbidity ( P trend = .08), and more advanced breast cancer stage ( P trend = .09).
D ISCUSSION
Among a community-based population in fi ve U.S. states, screening CBE failed to detect breast cancer in nearly four of fi ve women who ultimately died of breast cancer. The sensitivity of screening CBE among these women was substantially lower than in clinical trials of breast cancer screening. Sensitivity was statistically signifi cantly lower among women who were using estrogen or who received a Pap smear along with CBE.
Sensitivity of the screening CBE was also low in three other community-based studies ( 6 -8 ) . Among low-income women receiving examinations within the National Breast and Cervical Cancer Early Detection Program, CBE had a reported sensitivity of 59% ( 6 ) . Yet nearly half of cancer cases had breast symptoms at the time of CBE, so many of these examinations were performed for diagnosis rather than screening ( 6 , 9 ) . When only asymptomatic women were considered, sensitivity of the screening CBE was 36% ( 6 ) . Sensitivity was similarly low among women with invasive breast cancer receiving CBE from nurse examiners within one of the six health plans from which our study population derived ( 7 ) . One urban academic screening program reported a sensitivity of 28% ( 8 ) . Alongside these studies, the low rate of breast cancer detection in our study suggests that the performance of CBE by community-based clinicians differs substantially from CBE performance in clinical trials.
In studies using silicone breast models, the strongest predictor of lump detection was exam duration ( 11 ) . In the Canadian trial, examiners used a standard protocol with an average duration of 5 to 10 minutes, which likely contributed to the achievement of 69% sensitivity ( 16 ) . In contrast, a study in an ambulatory setting found that the average duration of clinical examination of both breasts was less than 2 minutes ( 17 ) . If the typical CBE in community practice is relatively brief, clinicians may be more likely to miss subtle breast cancers than examiners in clinical trials. We found that receiving a Pap smear concurrently with screening CBE was associated with reduced sensitivity, and there was a trend toward lower sensitivity among patients with greater chronic disease comorbidity. It is possible that providers may perform the screening CBE more quickly during visits that include other time-consuming clinical tasks, such as Pap smear screening or chronic illness care. Although failure to detect breast cancer during CBE is a common cause of malpractice allegations, time constraints in usual primary-care practice may not allow the performance of thorough, high-quality screening. Screening CBE was signifi cantly less sensitive among women using estrogen. Hormone replacement therapy was also associated with reduced CBE sensitivity among women screened at one urban academic program ( 8 ) . Hormone replacement reduces the sensitivity of screening mammography ( 18 ) , seemingly through its effect on breast density ( 19 ) . Although a similar effect on CBE sensitivity seems biologically plausible, our fi ndings confl ict with a study from one of the participating health plans, which reported increased CBE sensitivity among women using hormone replacement ( 7 ) . Also, our analysis did not account for progesterone usage, which may mediate the effect of hormone replacement on breast density ( 20 ) .
Cautious interpretation of our results is warranted because our sample of women with breast cancer may not be representative of the broader population of women who are diagnosed with breast cancer following CBE. All the women in our sample died of breast cancer. The women in our study may have had relatively aggressive cancers, which may have been more diffi cult to detect at screening than a population composed of women with a broader spectrum of cancer. Selection of more aggressive cases may explain the surprising trend toward reduced sensitivity among women with more advanced breast cancer stage at diagnosis, in contrast to previous studies that have found higher sensitivity with advanced stage ( 7 , 9 ) . Nonetheless, the sensitivity of CBE in a separate report ( 7 ) among a general population of women diagnosed with breast cancer within one of the participating health plans (including women who did not die) was very similar to the sensitivity among patients in our study from the same plan ( χ 2 [1 degree of freedom] = 0.09; P = .77) (data not shown to pre serve health plan confi dentiality). Moreover, our fi ndings are con sistent with those of two other community-based studies that found low screening CBE sensitivity ( 6 , 8 ) .
Our results may not be generalizable to women younger than 40 years or older than 65 years or to uninsured populations.
Although examinations in this study were performed between 1982 and 1993, we detected no secular improvement in sensitivity during this period, so we suspect that our estimate of CBE accuracy is refl ective of current community practice.
Strengths of this study include rigorous methods of chart abstraction and data quality assessment ( 12 ) , which make us confi dent that the CBEs we have studied were performed for screening rather than diagnosis. Also, we studied examinations performed by many community-based clinicians in fi ve U.S. states and evaluated the impact of a rich variety of demographic and clinical factors on examination outcomes. Our fi ndings suggest that CBE fails to detect breast cancer in many women who ultimately succumb to the disease. Thus, missed breast cancer with CBE appears to be a regrettably common outcome of current standards of community practice, leaving primary-care physicians who commonly perform CBE screening in a medicolegal quandary. Because neither the practice environment nor patient expectations are conducive to careful, high-quality CBE, physicians may need to choose whether to proceed with usual, brief CBE screening or to omit CBE screening altogether, yet neither choice will clearly attenuate physicians' risk of tort claims for missed breast cancer. We acknowledge, however, that even if practice environments facilitated more thorough CBE, physicians may require training in conducting high-quality CBE, and educational efforts may be needed to modify patient expectations regarding optimal CBE content and duration.
CBE achieved a high sensitivity in clinical trials ( 16 ) , a fi nding that indicates that physical examination could play an important role in breast cancer screening. However, the low detection rate in this community study suggests that the screening CBE in clinical practice frequently misses breast cancers that ultimately prove to be lethal. Clinicians and patients should be informed that a high-quality CBE likely requires minutes rather than seconds. Although clinicians should be encouraged to conduct the screening CBE in a deliberate fashion, improved CBE performance may require organizational interventions that support the delivery of high-quality preventive services in primary care. * OR = odds ratio; CI = confi dence interval. Adjusted for age in 5-year categories, health plan, and all listed variables.
† Modifi ed to include one point for hypertension. ‡ P trend = .08, two-sided. § P trend = .09, two-sided.
